文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克复苏液体:随机对照试验的网络Meta分析

Resuscitation Fluids in Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Shock · 2020-01-01
一句话结论网络Meta分析提示平衡液是脓毒性休克首选复苏液体,高分子量羟乙基淀粉与急性肾损伤及肾脏替代治疗需求增加相关,应避免使用。

该网络Meta分析纳入13项比较脓毒性休克复苏液体的随机对照试验,评估28天死亡率、90天死亡率、急性肾损伤发生率及肾脏替代治疗需求。结果显示各液体间28天和90天死亡率无显著差异;高分子量羟乙基淀粉较明胶、平衡液和低分子量羟乙基淀粉增加急性肾损伤风险,且较平衡液和生理盐水增加肾脏替代治疗需求;低分子量羟乙基淀粉较平衡液增加肾脏替代治疗需求。作者结论为平衡液是脓毒性休克的首选复苏液体,明胶需进一步评估,高分子量和低分子量羟乙基淀粉均应避免使用。

要点

  • 各复苏液体间28天死亡率和90天死亡率均无显著差异。
  • 高分子量羟乙基淀粉较明胶、平衡液和低分子量羟乙基淀粉增加急性肾损伤风险。
  • 高分子量羟乙基淀粉较平衡液和生理盐水增加肾脏替代治疗需求。
  • 低分子量羟乙基淀粉较平衡液增加肾脏替代治疗需求。
  • 作者结论:平衡液为脓毒性休克首选复苏液体,明胶需进一步评估,高分子量和低分子量羟乙基淀粉均应避免。

适用人群与场景

  • 脓毒性休克患者(纳入13项比较复苏液体的随机对照试验)

研究设计与关键结果

  • 研究类型:网络Meta分析,纳入13项随机对照试验,比较脓毒性休克复苏液体。
  • 主要终点:28天死亡率和90天死亡率在各液体间均无显著差异。
  • 28天死亡率SUCRA排名:高渗氯化钠/羟乙基淀粉40溶液最高(93.8%),其次为平衡液(69.6%)和白蛋白(61.9%)。
  • 90天死亡率SUCRA排名:明胶最高(75.1%),其次为平衡液(55.1%)和生理盐水(52.4%)。
  • 急性肾损伤:高分子量羟乙基淀粉较明胶、平衡液和低分子量羟乙基淀粉增加急性肾损伤风险;SUCRA排名明胶最高(74.4%),其次为生理盐水(64.9%)和平衡液(58.3%)。
  • 肾脏替代治疗:高分子量羟乙基淀粉较平衡液和生理盐水增加肾脏替代治疗需求,低分子量羟乙基淀粉较平衡液增加肾脏替代治疗需求;SUCRA排名生理盐水最高(91.6%),其次为平衡液(74.4%)和低分子量羟乙基淀粉(36.1%)。
  • 节点拆分分析和环路特异性分析未显示显著不一致性,漏斗图未显示发表偏倚。

证据类型、等级与局限

  • 证据类型:随机对照试验的网络Meta分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为平衡液是脓毒性休克的首选复苏液体。
  • 作者认为明胶的使用需要进一步评估。
  • 作者结论认为高分子量羟乙基淀粉与急性肾损伤和肾脏替代治疗的显著风险相关,低分子量羟乙基淀粉较平衡液增加肾脏替代治疗需求,两者均应避免用于脓毒性休克。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The aim of this study was to assess the efficacy and safety of various resuscitation fluids in septic shock by adopting a network meta-analysis (NMA). Randomized controlled trials (RCTs) comparing resuscitation fluids in septic shock were carried out by retrieving electronic databases. NMAs of 28-day mortality, 90-day mortality, incidence of acute kidney injury (AKI), and the need for renal replacement therapy (RRT) were conducted using the STATA 15.0 software. Probability-based ranking and surface under cumulative ranking (SUCRA) were performed to identify the optimal resuscitation fluid. Inconsistencies were evaluated by node-splitting analysis and a loop-specific approach. Furthermore, publication bias was analyzed by funnel plots. A total of 13 RCTs were enrolled in the analysis. The NMA results revealed that no significant differences were detected in the outcomes of 28-day mortality and 90-day mortality among various resuscitation fluids. The SUCRAs (the first indicates the best) of 28-day mortality showed that the hypertonic sodium chloride/hydroxyethyl starch 40 solution ranked the highest (93.8%), followed by the balanced solution (BS) (69.6%), and albumin (61.9%). On the other hand, the SUCRAs of 90-day mortality revealed that gelatin (GEL) ranked the highest (75.1%), followed by BS (55.1%), and NS (52.4%). The NMA results of AKI demonstrated that high-molecular-weight hydroxyethyl starch (H-HES) was associated with increased risk of AKI in comparison with GEL, BS, and L-HES. The SUCRAs of AKI showed that GEL ranked the highest (74.4%), followed by NS (64.9%), and BS (58.3%). In addition, the NMA results of RRT revealed that H-HES was associated with an increased need for RRT in comparison with BS and NS, and L-HES was associated with increased need of RRT in comparison with BS. The SUCRAs of RRT revealed that NS ranked the highest (91.6%), followed by BS (74.4%) and L-HES (36.1%). No significant inconsistencies were shown by the node-splitting analysis and no publication bias was demonstrated in the funnel plots. In conclusion, BS was determined as the preferred resuscitation fluid for septic shock. Moreover, the use of GEL requires further evaluation. H-HES was associated with a significant risk of AKI and RRT, whereas L-HES with an increased need for RRT compared with BS. Thus, both resuscitation fluids should be avoided for septic shock.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Li B, Zhao H, Zhang J, et al. Resuscitation Fluids in Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials. Shock. 2020. PMID: 31693630. doi:10.1097/SHK.0000000000001468

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。